5-(tributylstannyl)-[1,2,4]triazolo[1,5-a]pyridine | 1332076-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 5-(tributylstannyl)-[1,2,4]triazolo[1,5-a]pyridine
• 英文别名: tributyl([1,2,4]triazolo[1,5-a]pyridin-5-yl)stannane
• CAS: 1332076-55-7
• 化学式: C₁₈H₃₁N₃Sn
• 分子量: 408.174
• InChiKey: HWKSEVDTHDKFHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.79
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(tributylstannyl)-[1,2,4]triazolo[1,5-a]pyridine 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 反应 1.83h， 生成 N-(5-cyano-2-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}phenyl)acetamide
  参考文献：
  名称：

  1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction

  摘要：

  Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen -bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.

  DOI：

  10.1021/acs.jmedchem.7b00352
• 作为产物：
  描述：

  三丁基氯化锡 、 5-溴[1,2,4]三唑并[1,5-a]吡啶 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.17h， 生成 5-(tributylstannyl)-[1,2,4]triazolo[1,5-a]pyridine
  参考文献：
  名称：

  [EN] FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS
  [FR] DÉRIVÉS HÉTÉROARYLES BICYCLIQUES FUSIONNÉS AYANT UNE ACTIVITÉ D'INHIBITEURS DE PHD

  摘要：

  本发明提供了式（I）的化合物及其药用盐，式（I）中X1，X2，X3，Y1，Y2，R1，R2和R3如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。

  公开号：

  WO2016148306A1

文献信息

• [EN] FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES BICYCLIQUES FUSIONNÉS AYANT UNE ACTIVITÉ D'INHIBITEURS DE PHD
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2016148306A1

  公开（公告）日：2016-09-22

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein X1 , X2, X 3, Y1 , Y 2, R 1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物及其药用盐，式（I）中X1，X2，X3，Y1，Y2，R1，R2和R3如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Castanedo Georgette

  公开号：US20110207713A1

  公开（公告）日：2011-08-25

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I 化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制 PI3K 的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用 Formula I 化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病，或相关病理条件的方法。
• Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
  申请人：Genetech, Inc.

  公开号：US08563540B2

  公开（公告）日：2013-10-22

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I化合物，包括立体异构体、几何异构体、互变异构体、代谢产物和药学上可接受的盐，可用于抑制PI3K的δ异构体，并用于治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症。本文披露了使用公式I化合物进行哺乳动物细胞中的体内、体外和原位诊断、预防或治疗此类疾病或相关病理状况的方法。
• 1,2,4-Triazolo-[1,5-<i>a</i>]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction
  作者：Saleh Ahmed、Andrew Ayscough、Greg R. Barker、Hannah E. Canning、Richard Davenport、Robert Downham、David Harrison、Kerry Jenkins、Natasha Kinsella、David G. Livermore、Susanne Wright、Anthony D. Ivetac、Robert Skene、Steven J. Wilkens、Natalie A. Webster、Alan G. Hendrick

  DOI：10.1021/acs.jmedchem.7b00352

  日期：2017.7.13

  Herein we describe the identification of 4-[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen -bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.